Kyung-Sup Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kyung-Sup Kim has a total of 291 co-authors. Here are the top co-authors by number of shared publications:
- Yong-Ho Ahn
Department of Biochemistry and Molecular Biology, Yonsei University College of Medicine, Seoul 120-752, Republic of Korea
16 shared publications - Man-Wook Hur
American Society for Biochemistry and Molecular Biology
14 shared publications - Sahng Wook Park
Department of Biochemistry and Molecular Biology, Institute of Genetic Science, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Republic of Korea
12 shared publications Dong-In Koh
Brain Korea 21 Plus Project for Medical Sciences, Department of Biochemistry and Molecular Biology, Severance Biomedical Research Institute, Yonsei University School of Medicine, 50-1 Yonsei-Ro, SeoDaeMoon-Ku, Seoul 03722, Korea
11 shared publicationsBu-Nam Jeon
BK21 plus project of Medical Science, Department of Biochemistry and Molecular Biology, Yonsei University School of Medicine, 50-1 Yonsei-Ro, SeoDaeMoon-Ku, Seoul 03722, Republic of Korea
10 shared publicationsMin-Kyeong Kim
Brain Korea 21 Plus Project for Medical Sciences, Department of Biochemistry and Molecular Biology, Severance Biomedical Research Institute, Yonsei University School of Medicine, 50-1 Yonsei-Ro, SeoDaeMoon-Ku, Seoul 03722, Korea
8 shared publications
Latest Publications
- Open Access
- 25 January 2023
- Published by Elsevier in Molecular Therapy Nucleic Acids
- Vol. 31, 398-410
Exon definitive regions for MPC1 microexon splicing and its usage for splicing modulation
- 25 January 2023
- Published by Elsevier in Molecular Therapy Nucleic Acids
- Vol. 31, 398-410
Open AccessExon definitive regions for MPC1 microexon splicing and its usage for splicing modulation
- Open Access
- 1 August 2019
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 294 (35) , 12957-12974
Temporal and differential regulation of KAISO-controlled transcription by phosphorylated and acetylated p53 highlights a crucial regulatory role of apoptosis
- 1 August 2019
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 294 (35) , 12957-12974
Open AccessTemporal and differential regulation of KAISO-controlled transcription by phosphorylated and acetylated p53 highlights a crucial regulatory role of apoptosis
- 1 August 2019
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms
- Vol. 1862 (8) , 771-785
Hypoxia-induced RelA/p65 derepresses SLC16A3 (MCT4) by downregulating ZBTB7A
- 1 August 2019
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms
- Vol. 1862 (8) , 771-785
Hypoxia-induced RelA/p65 derepresses SLC16A3 (MCT4) by downregulating ZBTB7A
- Open Access
- 25 May 2019
- Published by Wiley in FEBS Letters
- Vol. 593 (14) , 1763-1776
HIC2, a new transcription activator of SIRT1
The protein deacetylase SIRT1 is crucial to numerous physiological processes, such as aging, metabolism, and autoimmunity, and is repressed by various transcription factors, including HIC1. Conversely, we found that HIC2, which is highly homologous to HIC1, is a transcriptional activator of SIRT1 due to opposite activity of the intermediate domains of the two homologs. Importantly, this relationship between HIC2 and SIRT1 could be important for cardiac development, where both proteins are implicated. Here, we assessed whether ectopic expression of HIC2, and subsequent upregulation of SIRT1, might decrease apoptosis in H9c2 cardiomyocytes under simulated ischemia/reperfusion (I/R) injury conditions. Our results demonstrate that unlike its structural homolog HIC1, HIC2 is a pivotal transcriptional activator of SIRT1 and, consequently, may protect the heart from I/R injury.
- 25 May 2019
- Published by Wiley in FEBS Letters
- Vol. 593 (14) , 1763-1776
Open AccessHIC2, a new transcription activator of SIRT1
The protein deacetylase SIRT1 is crucial to numerous physiological processes, such as aging, metabolism, and autoimmunity, and is repressed by various transcription factors, including HIC1. Conversely, we found that HIC2, which is highly homologous to HIC1, is a transcriptional activator of SIRT1 due to opposite activity of the intermediate domains of the two homologs. Importantly, this relationship between HIC2 and SIRT1 could be important for cardiac development, where both proteins are implicated. Here, we assessed whether ectopic expression of HIC2, and subsequent upregulation of SIRT1, might decrease apoptosis in H9c2 cardiomyocytes under simulated ischemia/reperfusion (I/R) injury conditions. Our results demonstrate that unlike its structural homolog HIC1, HIC2 is a pivotal transcriptional activator of SIRT1 and, consequently, may protect the heart from I/R injury.
- Open Access
- 1 January 2019
- Published by The Korean Urological Association in Investigative and Clinical Urology
- Vol. 60 (6) , 425-431
Prolyl hydroxylase-3 is a novel renal cell carcinoma biomarker
Purpose: The aim of this study was to determine the suitability of serum prolyl hydroxylase-3 (PHD3) as a diagnostic or monitoring biomarker of renal cell carcinoma (RCC). Materials and Methods: Between October 2013 and March 2015, we prospectively recruited study participants. The RCC group consisted of 56 patients who underwent radical or partial nephrectomy. The control group included 56 healthy kidney donors and 13 patients with benign renal masses. Blood from the RCC patients was sampled prior to surgery and again 1 and 3 months after the operation. Serum PHD3 levels were measured via enzyme-linked immunosorbent assay and compared between RCC patients and controls. Results: RCC patients had higher serum PHD3 levels than controls (0.79 +/- 0.17 ng/mL vs. 0.73 +/- 0.09 ng/mL, p=0.023), with an area under curve (AUC) of 0.668. With a cutoff value of 0.761 ng/ml, the sensitivity, specificity, positive predictive value, and negative predictive value were 66.1%, 68.1%, 28.8%, and 37.3%, respectively. No significant difference in PHD3 level was observed between healthy kidney donors and patients with benign renal masses. The predictive performance of PHD3 was improved in subgroup analyses of RCC patients with a tumor size >2 cm (n=40) or clear-cell histology (n=44), with AUCs of 0.709 and 0.688, respectively. Among 37 patients with PHD3 levels greater than the cutoff value of 0.761 ng/mL, the postoperative PHD3 levels at 1 and 3 months were significantly lower than the preoperative PHD3 levels (both p<0.001). Conclusions: Serum PHD3 represents a novel RCC biomarker that shows acceptable diagnostic performance.
- 1 January 2019
- Published by The Korean Urological Association in Investigative and Clinical Urology
- Vol. 60 (6) , 425-431
Open AccessProlyl hydroxylase-3 is a novel renal cell carcinoma biomarker
Purpose: The aim of this study was to determine the suitability of serum prolyl hydroxylase-3 (PHD3) as a diagnostic or monitoring biomarker of renal cell carcinoma (RCC). Materials and Methods: Between October 2013 and March 2015, we prospectively recruited study participants. The RCC group consisted of 56 patients who underwent radical or partial nephrectomy. The control group included 56 healthy kidney donors and 13 patients with benign renal masses. Blood from the RCC patients was sampled prior to surgery and again 1 and 3 months after the operation. Serum PHD3 levels were measured via enzyme-linked immunosorbent assay and compared between RCC patients and controls. Results: RCC patients had higher serum PHD3 levels than controls (0.79 +/- 0.17 ng/mL vs. 0.73 +/- 0.09 ng/mL, p=0.023), with an area under curve (AUC) of 0.668. With a cutoff value of 0.761 ng/ml, the sensitivity, specificity, positive predictive value, and negative predictive value were 66.1%, 68.1%, 28.8%, and 37.3%, respectively. No significant difference in PHD3 level was observed between healthy kidney donors and patients with benign renal masses. The predictive performance of PHD3 was improved in subgroup analyses of RCC patients with a tumor size >2 cm (n=40) or clear-cell histology (n=44), with AUCs of 0.709 and 0.688, respectively. Among 37 patients with PHD3 levels greater than the cutoff value of 0.761 ng/mL, the postoperative PHD3 levels at 1 and 3 months were significantly lower than the preoperative PHD3 levels (both p<0.001). Conclusions: Serum PHD3 represents a novel RCC biomarker that shows acceptable diagnostic performance.
- Open Access
- 1 January 2019
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 294 (1) , 299-313
Reciprocal negative regulation between the tumor suppressor protein p53 and B cell CLL/lymphoma 6 (BCL6) via control of caspase-1 expression
- 1 January 2019
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 294 (1) , 299-313
Open AccessReciprocal negative regulation between the tumor suppressor protein p53 and B cell CLL/lymphoma 6 (BCL6) via control of caspase-1 expression
- 1 June 2018
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 140, 107-117
Fasting serum amino acids concentration is associated with insulin resistance and pro-inflammatory cytokines
- 1 June 2018
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 140, 107-117
Fasting serum amino acids concentration is associated with insulin resistance and pro-inflammatory cytokines
- 18 May 2018
- Published by Portland Press Ltd. in Biochemical Journal
- Vol. 475 (10) , 1687-1699
MPC1 is essential for PGC-1α-induced mitochondrial respiration and biogenesis
Mitochondrial pyruvate carrier (MPC), which is essential for mitochondrial pyruvate usage, mediates the transport of cytosolic pyruvate into mitochondria. Low MPC expression is associated with various cancers, and functionally associated with glycolytic metabolism and stemness. However, the mechanism by which MPC expression is regulated is largely unknown. In this study, we showed that MPC1 is down-regulated in human renal cell carcinoma (RCC) due to strong suppression of peroxisome proliferator-activated receptor-gamma co-activator (PGC)-1 alpha (PGC-1α). We also demonstrated that overexpression of PGC-1α stimulates MPC1 transcription, while depletion of PGC-1α by siRNA suppresses MPC expression. We found that PGC-1α interacts with estrogen-related receptor-alpha (ERR-α) and recruits it to the ERR-α response element motif located in the proximal MPC1 promoter, resulting in efficient activation of MPC1 expression. Furthermore, the MPC inhibitor, UK5099, blocked PGC-1α-induced pyruvate-dependent mitochondrial oxygen consumption. Taken together, our results suggest that MPC1 is a novel target gene of PGC-1α. In addition, low expression of PGC-1α in human RCC might contribute to the reduced expression of MPC, resulting in impaired mitochondrial respiratory capacity in RCC by limiting the transport of pyruvate into the mitochondrial matrix.
- 18 May 2018
- Published by Portland Press Ltd. in Biochemical Journal
- Vol. 475 (10) , 1687-1699
MPC1 is essential for PGC-1α-induced mitochondrial respiration and biogenesis
Mitochondrial pyruvate carrier (MPC), which is essential for mitochondrial pyruvate usage, mediates the transport of cytosolic pyruvate into mitochondria. Low MPC expression is associated with various cancers, and functionally associated with glycolytic metabolism and stemness. However, the mechanism by which MPC expression is regulated is largely unknown. In this study, we showed that MPC1 is down-regulated in human renal cell carcinoma (RCC) due to strong suppression of peroxisome proliferator-activated receptor-gamma co-activator (PGC)-1 alpha (PGC-1α). We also demonstrated that overexpression of PGC-1α stimulates MPC1 transcription, while depletion of PGC-1α by siRNA suppresses MPC expression. We found that PGC-1α interacts with estrogen-related receptor-alpha (ERR-α) and recruits it to the ERR-α response element motif located in the proximal MPC1 promoter, resulting in efficient activation of MPC1 expression. Furthermore, the MPC inhibitor, UK5099, blocked PGC-1α-induced pyruvate-dependent mitochondrial oxygen consumption. Taken together, our results suggest that MPC1 is a novel target gene of PGC-1α. In addition, low expression of PGC-1α in human RCC might contribute to the reduced expression of MPC, resulting in impaired mitochondrial respiratory capacity in RCC by limiting the transport of pyruvate into the mitochondrial matrix.
- Open Access
- 15 September 2017
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (47) , 82940-82955
Lack of both androgen receptor and forkhead box A1 (FOXA1) expression is a poor prognostic factor in estrogen receptor-positive breast cancers
// <![CDATA[ $('.header-date').hide();$('#titleAuthors').hide();$('#abstractHeader').hide(); // ]]> Seho Park1, 2, *, Eunjin Koh3, *, Ja Seung Koo4, Seung Il Kim1, Byeong-Woo Park1 and Kyung-Sup Kim3 1Department of Surgery, Yonsei University College of Medicine, Seoul, South Korea 2Frontier Research Institute of Convergence Sports Science, Yonsei University, Seoul, South Korea 3Department of Biochemistry and Molecular Biology, Institute for Genetic Science, Integrated Genomic Research Center for Metabolic Regulation, Yonsei University College of Medicine, Seoul, South Korea 4Department of Pathology, Yonsei University College of Medicine, Seoul, South Korea *These authors have contributed equally to this work Correspondence to: Seung Il Kim, email: skim@yuhs.ac Kyung-Sup Kim, email: kyungsup59@yuhs.ac Keywords: androgen receptor, breast neoplasms, estrogen receptor, forkhead box A1, prognosis Received: February 02, 2017 Accepted: July 18, 2017 Published: September 15, 2017 ABSTRACT The present study aimed to examine the associations between androgen receptor (AR) and forkhead box A1 (FOXA1) and to investigate clinicopathological features and survival according to both biomarker status in estrogen receptor (ER)-positive breast cancers using in vitro study, patient cohort data, and the cBioPortal for Cancer Genomics and Kaplan-Meier Plotter websites. Experiments using T47D and ZR75-1 demonstrated AR-overexpressing cell lines decreased in cell proliferation through downregulation of ER, but FOXA1 did not change. Knockdown of FOXA1 resulted in a significantly reduced cell viability. Patients with immunohistochemically AR(-)/FOXA1(-) tumor frequently showed node metastasis, high grade, and high Ki-67 proliferation, therefore, significantly worse survival in ER-positive disease. AR and FOXA1 mRNA levels were significantly higher in ER-positive than in ER-negative tumors and AR-low/FOXA1-low tumors showed high grade, frequent basal-like subtype and worse disease-free survival in ER-positive cancers of public gene dataset, similarly to patient cohort results. The Kaplan-Meier Plotter analysis independently validated patients with both low AR/FOXA1 tumor were significantly associated with worse relapse-free survival in ER-positive cancers. This study suggests that distinctive clinicopathological features according to AR and FOXA1 are determined and a lack of both biomarkers is an independent poor prognostic factor in ER-positive tumors.
- 15 September 2017
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (47) , 82940-82955
Open AccessLack of both androgen receptor and forkhead box A1 (FOXA1) expression is a poor prognostic factor in estrogen receptor-positive breast cancers
// <![CDATA[ $('.header-date').hide();$('#titleAuthors').hide();$('#abstractHeader').hide(); // ]]> Seho Park1, 2, *, Eunjin Koh3, *, Ja Seung Koo4, Seung Il Kim1, Byeong-Woo Park1 and Kyung-Sup Kim3 1Department of Surgery, Yonsei University College of Medicine, Seoul, South Korea 2Frontier Research Institute of Convergence Sports Science, Yonsei University, Seoul, South Korea 3Department of Biochemistry and Molecular Biology, Institute for Genetic Science, Integrated Genomic Research Center for Metabolic Regulation, Yonsei University College of Medicine, Seoul, South Korea 4Department of Pathology, Yonsei University College of Medicine, Seoul, South Korea *These authors have contributed equally to this work Correspondence to: Seung Il Kim, email: skim@yuhs.ac Kyung-Sup Kim, email: kyungsup59@yuhs.ac Keywords: androgen receptor, breast neoplasms, estrogen receptor, forkhead box A1, prognosis Received: February 02, 2017 Accepted: July 18, 2017 Published: September 15, 2017 ABSTRACT The present study aimed to examine the associations between androgen receptor (AR) and forkhead box A1 (FOXA1) and to investigate clinicopathological features and survival according to both biomarker status in estrogen receptor (ER)-positive breast cancers using in vitro study, patient cohort data, and the cBioPortal for Cancer Genomics and Kaplan-Meier Plotter websites. Experiments using T47D and ZR75-1 demonstrated AR-overexpressing cell lines decreased in cell proliferation through downregulation of ER, but FOXA1 did not change. Knockdown of FOXA1 resulted in a significantly reduced cell viability. Patients with immunohistochemically AR(-)/FOXA1(-) tumor frequently showed node metastasis, high grade, and high Ki-67 proliferation, therefore, significantly worse survival in ER-positive disease. AR and FOXA1 mRNA levels were significantly higher in ER-positive than in ER-negative tumors and AR-low/FOXA1-low tumors showed high grade, frequent basal-like subtype and worse disease-free survival in ER-positive cancers of public gene dataset, similarly to patient cohort results. The Kaplan-Meier Plotter analysis independently validated patients with both low AR/FOXA1 tumor were significantly associated with worse relapse-free survival in ER-positive cancers. This study suggests that distinctive clinicopathological features according to AR and FOXA1 are determined and a lack of both biomarkers is an independent poor prognostic factor in ER-positive tumors.